A Safety and Efficacy Trial of TTHX1114 in People With CED

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2021

Primary Completion Date

August 29, 2023

Study Completion Date

October 31, 2023

Conditions

Corneal Endothelial Dystrophy

Interventions

DRUG

TTHX1114

engineered FGF-1

Trial Locations (2)

Trefoil Study Site, Washington

Trefoil Study Site, Atlanta

All Listed Sponsors

lead

Trefoil Therapeutics, Inc.

INDUSTRY

NCT04812067 - A Safety and Efficacy Trial of TTHX1114 in People With CED | Biotech Hunter | Biotech Hunter